Exploring the risks and opportunities in the synthetic biology industry, including the ability for individuals to edit genes in their garages. Discussing Ginko Bio Works' goal of building an enabling infrastructure for synthetic biology and the business model of biology. Exploring the potential dangers and responsible biosecurity measures in gene editing. Exploring advancements in genetic diagnostics and exciting changes in the field. Learning about Kinva's use of microbes to convert waste gases into animal feed and discussing the potential risks of synthetic biology.
Read more
AI Summary
AI Chapters
Episode notes
auto_awesome
Podcast summary created with Snipd AI
Quick takeaways
Ginkgo Bioworks focuses on building the infrastructure and providing biology as a service, enabling a wide range of drugs to get to market.
The rapid growth of synthetic biology poses concerns regarding biosecurity and the need for responsible development and discussions around biotechnology's advancement.
Deep dives
Ginkgo BioWorks: Building Biology as a Service
Ginkgo BioWorks is a company at the forefront of synthetic biology, focusing on building the infrastructure and platform that enables companies of all sizes and industries to use a biological toolkit. By investing in the physical infrastructure and building the necessary IP and data, Ginkgo aims to make it easier to engineer biology. While many companies in the sector focus on product creation, Ginkgo takes a unique approach as a provider of biology as a service. They recognize the value in enabling a wide range of drugs to get to market, rather than solely focusing on individual drug success.
Balancing Opportunities and Risks in Synthetic Biology
Synthetic biology holds immense promise and potential for disrupting industries, accounting for a significant portion of global GDP. However, this disruption is not without risks. One major concern is the potential for misuse, such as bioterrorism or the creation of deadly pathogens by unauthorized individuals or non-state actors. While regulations exist, they may not be adequately equipped to address the rapid growth of synthetic biology. Biosecurity is seen as a crucial area for growth and vigilance, with experts emphasizing the need for responsible development and profound discussions around the terms and conditions of biotechnology's advancement.
Nostos Genomics is leveraging synthetic biology and advanced sequencing technologies to simplify medical diagnostics for rare genetic diseases. By analyzing genetic variants and predicting their effects at the molecular and clinical levels, Nostos Genomics aims to provide faster and more accurate diagnoses. The development of technologies such as sequencing, synthetic DNA creation, and genome editing has transformed the field. With these advancements, previously untreatable diseases can now be addressed, offering a paradigm shift in healthcare.
For all the exciting developments in the synthetic biology industry, there are also concerns.
People can edit genes in their garages these days, so who’s regulating this space?
Plus - we’ll hear about the exciting new business models with biology at their core, including one of the first synbio businesses to trade as a public stock - Ginkgo Bioworks.